SAN DIEGO, CA – August 23, 2023 - Antharis Therapeutics, a four-year-old biopharmaceutical company developing a leading portfolio of oncology-related immunotherapeutics, today announced the completion of its acquisition of Galileo Biotech. This exciting acquisition includes a state-of-the-art R&D laboratory and a GMP-certified manufacturing facility. The combination with Galileo grows Antharis’ capabilities for accelerating the development of its extensive portfolio of assets. In particular, it provides GMP-certified facilities to support research, development and manufacturing as therapeutic assets move toward clinical trials. The conclusion of this transaction -- the company's second acquisition in as many years - maintains Antharis on a path of explosive growth. The deal further highlights Antharis' position at the leading edge of biotechnology - generating high-potential biological assets for the treatment of a number of cancer types, in multiple therapeutic classes.
“The acquisition of Galileo is another major milestone for Antharis. This transaction brings GMP capacity, cost savings, enhanced productivity, in-vitro diagnostics capabilities, and further strategic advantages to our company. Moreover, this acquisition puts us in a better position to pursue clinical studies of our most advanced assets”, said Dr. Raphael Ribeiro-Pinaud, CEO & Chairman of Antharis Therapeutics. “Seeing Galileo join the Antharis family of companies speaks to the vision we had in creating Galileo and to the therapeutic importance of what Antharis is achieving,” said Emmanuel Hermann, CEO & Founder of Leste Group and primary Galileo investor. Antharis leverages its state-of-the-art platform for the discovery, development, and validation of monoclonal antibody assets in the oncology field. The company’s cutting-edge science and unique approach to approaching biotherapeutic development has been successfully validatingassets at a significantly higher rate than the industry norm. This has allowed Antharis to grow one of the largest preclinical portfolios of monoclonal antibodiesin the industry. Antharis, which is actively expanding its workforce, will begin pre-IND work on a significant selection of advanced assets this year.
About Antharis Therapeutics
Antharis Therapeutics Inc. is a biopharmaceutical company involved in the discovery and development of immunotherapeutics to address devastating diseases for which there are limited or unsatisfactory treatment options. Antharis is focused on oncological (cancer) diseases, as this is one of the largest markets in need of therapies and where our team has its greatest expertise. Antharis is based in the Greater San Diego Area, California, one of the prime biotechnology hubs in the world and is led by Dr. Raphael Ribeiro-Pinaud, CEO & Chairman. For more information, visit www.antharistherapeutics.com.
About Galileo Biotech, an Antharis Therapeutics Company
Galileo Biotech is a science-driven company focused on the development and production of cutting-edge therapeutic monoclonal antibodies for devastating human diseases, in particular cancer, as well as in-vitro immunodiagnostic products. The company, including its state-of-the-art R&D and manufacturing facilities, is based in the city of Rio de Janeiro, Brazil and is now headquartered in the Greater San Diego Area, California. Galileo is the first company in Brazil to obtain GMP certification for the full workflow of research, development and manufacturing of its immunochemistry diagnostic products.
